Drug profile

The FDA adverse-event record for Milbemycin + Spinosad

42 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Milbemycin + Spinosad. Species, reactions, and outcomes follow.

#1231 of 2,679
by report volume (all drugs)
42
adverse-event reports
14.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Milbemycin + Spinosad ranks #1222 of 2679 by total reports (42). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1222
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Milbemycin + Spinosad has 42 reports now versus 42 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Milbemycin + Spinosad changes

Signature read: death-coded share at 14.3% is the most distinctive stamp on Milbemycin + Spinosad's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
42
Total Reports
6
Deaths Reported
14.3%
Death-coded share of reports

Active Ingredients

MilbemycinSpinosad

Administration Routes

OralUnknownTopical

Species Affected

Dog 42

Most Affected Breeds

Maltese 5
Retriever - Labrador 4
Dog (unknown) 4
Terrier - Yorkshire 3
Retriever - Golden 3
Crossbred Canine/dog 2
Chihuahua 1
Terrier - Boston 1
Bichon Frise 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Vomiting 15
Lack of efficacy - NOS 9
Lethargy (see also Central nervous system depression in 'Neurological') 8
Lack of efficacy (ectoparasite) - flea 6
Seizure NOS 6
Diarrhoea 6
Behavioural disorder NOS 4
Anorexia 4
Death by euthanasia 3
PR-LIVER, LESION(S) 3
Pruritus 2
Bloody diarrhoea 2

Outcome Breakdown

Recovered/Normal
16 (39.0%)
Outcome Unknown
12 (29.3%)
Ongoing
7 (17.1%)
Died
3 (7.3%)
Euthanized
3 (7.3%)

Milbemycin + Spinosad Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Milbemycin + Spinosad (#1231 of 2,679 by report volume); death-coded 14.3%. PlainBreed drug row · death-coded share stamp 14.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →